Mucosal Immunization: A Review of Strategies and Challenges

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 31, Issue 4, 2014, Pages 273-303

  Patel, Hinal ^a   Yewale, Chetan ^a   Rathi, Mohan ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Mucosal immunization, vaccines, systemic infections, mucosal adjuvant, antigen delivery systems, immunotherapeutics

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CONJUGATE VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CRUCELL; CYTOKINE; FLAGELLIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSTIMULATORY COMPLEX; INFLUENZA VACCINE; LIPOSOME; LIVE VACCINE; MEMBRANE ANTIGEN; ORAL POLIOMYELITIS VACCINE; PHOSPHORYL LIPID A; POLIOMYELITIS VACCINE; POLYMER; PROTOLLIN; QS 21; RECOMBINANT VECTOR; ROTAVIRUS VACCINE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIROSOME; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR; VIVOTIF L; VIVOTIL; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BIODEGRADABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLERA; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INFLUENZA; INNATE IMMUNITY; MUCOSAL DISEASE; MUCOSAL IMMUNIZATION; NASAL MUCOSAL IMMUNIZATION; NONHUMAN; POLIOMYELITIS; ROTAVIRUS INFECTION; T LYMPHOCYTE; TRANSGENIC PLANT; TYPHOID FEVER; VACCINATION; IMMUNOLOGY; MUCOSAL ADMINISTRATION; MUCOSAL IMMUNITY; PROCEDURES;

ADMINISTRATION, MUCOSAL; HUMANS; IMMUNITY, MUCOSAL; VACCINATION; VACCINES;

EID: 84903374147     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014010102     Document Type: Article

References (161)

1. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol. 2004;5(10):971-4.
2. Iwasaki A. Mucosal dendritic cells. Annu Rev Immunol. 2007;25:381-418.
3. Kagnoff MFaLE. Epithelial cells as sensors for microbial infection. J Clin Invest. 1997;100 (1):6.
4. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148-58.
5. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307(5717):1920-5.
6. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229-41.
7. Mantis N, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 2011;4(6):603-11.
8. Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman J-P, Lamm ME. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci U S A. 1991;88(19):8796-800.
9. Van Egmond M, Damen CA, Van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JG. IgA and the IgA Fc receptor. Trends Immunol. 2001;22(4):205-11.
10. Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML, Neutra MR. Secretory Immunoglobulin A antibodies against the σ1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol. 2004;78(2):947-57.
11. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME. A mucosal IgA-mediated excretory immune system in vivo. J Immunol. 2001;166(6):3688-92.
12. Black KP, Cummins Jr JE, Jackson S. Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity. Clin Immunol Immunopathol. 1996;81(2):182-90.
13. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol. 2002;169(1):566-74.
14. Eriksson K, Quiding-Jarbrink M, Osek J, Moller A, Bjork S, Holmgren J, Czerkinsky C. Specificantibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun. 1998;66(12):5889-96.
15. Parr EL, Parr MB. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol. 1997;71(11):8109-15.
16. Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen F-E, Nilsen EM, Yamanaka T. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today. 1999;20(3):141-51.
17. O'leary A, Sweeney E. Lymphoglandular complexes of the colon: structure and distribution. Histopathology. 1986;10(3):267-83.
18. Miller C, McChesney M, Moore P. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest. 1992;67(5):628-34.
19. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, Reinecker HC. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307(5707):254-8.
20. Neutra MR, Mantis NJ, Kraehenbuhl J-P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol. 2001;2(11):1004-9.
21. Hopkins S, Niedergang F, Corthesy-Theulaz I, Kraehenbuhl J. A recombinant Salmonella typhimurium vaccine strain is taken up and survives within murine Peyer's patch dendritic cells. Cell Microbiol. 2000;2(1):59-68.
22. Anosova N, Chabot S, Shreedhar V, Borawski J, Dickinson B, Neutra M. Cholera toxin, E. coli heatlabile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol. 2008;1(1):59-67.
23. Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8α+, and double-negative Peyer's patch dendritic cells. J Immunol. 2001;166(8):4884-90.
24. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol. 2003;3(1):63-72.
25. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004;4(6):407-19.
26. MacPherson G, Liu L. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Defense of mucosal surfaces: pathogenesis, immunity and vaccines: Springer; 1999. p. 33-53.
27. Holt P, Schon-Hegrad M, McMenamin P. Dendritic cells in the respiratory tract. Int Rev Immunol. 1990;6(2-3):139-49.
28. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. 2003;3(10):822-9.
29. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, VonAndrian UH. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003;424(6944): 88-93.
30. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7(4):265-76.
31. Qimron U, Paul L, Bar-Haim E, Bloushtain N, Eisenbach L, Staats HF, Porgador A. Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine. 2004;22(11):1390-4.
32. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses. 1997;13(11):945-52.
33. Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, Fujihashi K, Someya K, Honda M, McGhee JR, Kiyono H. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol. 1998;161(11):5952-8.
34. Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun. 1999;67(6):2884-90.
35. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis. 1998;177(5):1155-61.
36. Quiding M, Nordström I, Kilander A, Andersson G, Hanson L, Holmgren J, Czerkinsky C. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest. 1991;88(1):143.
37. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 1997;65(4):1387-94.
38. Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun. 2001;69(6):4125-8.
39. Johansson E-L, Wassén L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 2001;69(12):7481-6.
40. Johansson E-L, Bergquist C, Edebo A, Johansson C, Svennerholm A-M. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine. 2004;22(8): 984-90.
41. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol. 2009;70(6):505-15.
42. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11:S45-S53.
43. Cranage M, Fraser C, Stevens Z, Huting J, Chang M, Jeffs S, Seaman MS, Cope A, Cole T, Shattock RJ. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol. 2009;3(1):57-68.
44. Neutra MR, Pringault E, Kraehenbuhl J-P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol. 1996;14(1):275-300.
45. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307:178-80.
46. Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-35.
47. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151(3):420-36.
48. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
49. Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccines. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 1999 Jan;103(1):171-2.
50. Sánchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol. 2005;17(4):388-98.
51. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec. 2010 2010;85(13):117-28.
52. Lucas ME, Deen JL, von Seidlein L, Wang X-Y, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med. 2005;352(8):757-67.
53. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun. 1999;67(12):6341-5.
54. Levine M, Kaper J. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur. 1995;93(4):243-53.
55. Richie E, Punjabi NH, Sidharta Y, Peetosutan K, Sukandar M, Wasserman SS, Lesmana M, Wangsasaputra F, Pandam S, Levine MM, O'Hanley P, Cryz SJ, Simanjuntak CH. Efficacy trial of singledose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000;18(22):2399-410.
56. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9702):1694-702.
57. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, Holmgren J, Clemens JD, Sur D. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine. 2009;27(49):6887-93.
58. WHO. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83:49-59.
59. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha M, Cadoz M, Dominique S, Jacques A, Dolores AB, Birger T, Tod C, Rachel S, John BR. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med. 1987;317(18):1101-4.
60. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996;14(5):435-8.
61. Ferreccio C, Ortiz E, Cryz S, Levine M. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. The Lancet. 1990;336(8720):891-4.
62. WHO. Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2013;88:49-64.
63. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirusbased human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis. 1996;174(Supplement 1):S65-S72.
64. Bines JE. Rotavirus vaccines and intussusception risk. Curr Opin Gastroen. 2005;21(1):20-5.
65. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev. 2008;21(1):198-208.
66. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.
67. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebocontrolled trial. Lancet. 1999;354(9175):287-90.
68. O'Ryan M, Lucero Y, Linhares AC. Rotarix®: vaccine performance 6 years postlicensure. Expert Rev Vaccines. 2011;10(12):1645-59.
69. Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, Ball R, Iskander J, Parashar UD. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics. 2008;121(6):1206-12.
70. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Rüttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.
71. Cox R, Brokstad K, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59(1):1-15.
72. Belshe R, Lee M-S, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines. 2004;3(6):643-54.
73. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine. 2003;21:S89-S95.
74. AK Seth, A Misra. Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. J Pharm Pharm Sci. 2002; 5 (3): 285-291.
75. Hall LJ, Clare S, Pickard D, Clark SO, Kelly DL, Ghany MAE, Hale C, Dietrich J, Philip PA, Marsh D, Dougana G. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine. 2009;27(49):6894-904.
76. Boyer JD, Robinson TM, Maciag PC, Peng X, Johnson RS, Pavlakis G, Lewis MG, Shen A, Siliciano R, Brown CR, Weiner DB, Paterson Y. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology. 2005;333(1):88-101.
77. Mayr UB, Haller C, Haidinger W, Atrasheuskaya A, Bukin E, Lubitz W, Ignatyev G. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157: H7 bacterial ghosts protects mice against lethal challenge. Infect Immun. 2005;73(8):4810-7.
78. Di Fabio S, Medaglini D, Rush CM, Corrias F, Panzini GL, Pace M, Verani P, Pozzi G, Titti F. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine. 1998 Mar;16(5):485-92.
79. Mestecky J, McGhee JR. Prospects for human mucosal vaccines. Adv Exp Med Biol. 1991;327:13-23.
80. Morrow C, Novak M, Ansardi D, Porter D, Moldoveanu Z. Recombinant viruses as vectors for mucosal immunity. Defense of mucosal surfaces: pathogenesis, immunity and vaccines. Springer; 1999. p. 255-73.
81. Rosenthal KL, Gallichan WS, editors. Challenges for vaccination against sexually transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Seminars in immunology. Elsevier: 1997.
82. Buge S, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol. 1997;71(11):8531-41.
83. Attridge SR, Davies R, LaBrooy JT. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine. 1997 Feb;15(2):155-62.
84. Killeen K, Spriggs D, Mekalanos J. Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. Defense of mucosal surfaces: pathogenesis, immunity and vaccines. Springer: 1999. p. 237-54.
85. Baca-Estrada M, Foldvari M, Snider M. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res. 1999;19(5):455-62.
86. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol. 2004; 9(3):277-89.
87. Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surfacelinked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun. 1998;66(9):4299-304.
88. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol. 1997;159(7):3638-47.
89. Okada Ji, Cohen S, Langer R. In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm Res. 1995;12(4):576-82.
90. Deshmukh DS, Bear WD, Brockerhoff H. Can intact liposomes be absorbed in the gut? Life Sciences. 1981;28(3):239-42.
91. Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (Lipodine™)-mediated DNA vaccination by the oral route. J Liposome Res. 2002;12(1-2):185-97.
92. Mirchamsy H, Manhouri H, Hamedi M, Ahourai P, Fateh G, Hamzeloo Z. Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Biologicals. 1996;24(4):343-50.
93. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674-81.
94. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009;61(2):140-57.
95. Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials. 2008;29(6):703-8.
96. Primard C, Rochereau N, Luciani E, Genin C, Delair T, Paul S, Verrier B. Traffic of poly (lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials. 2010;31(23):6060-8.
97. Csaba N, Sanchez A, Alonso M. PLGA: poloxamer and PLGA: poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release. 2006;113(2):164-72.
98. Bhavsar MD, Amiji MM. Polymeric nano-and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv. 2007;4:197-213.
99. Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines. 2008;7:1341-56.
100. Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal, R. Vardaxis, N. Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm. 2007;4(1):73-84.
101. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4):394-407.
102. Roy K, Mao H-Q, Huang S-K, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387-91.
103. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine. 2003;21(5):341-6.
104. Erbacher P, Zou S, Bettinger T, Steffan A-M, Remy J-S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res. 1998;15(9):1332-9.
105. Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm. 2008;354(1):235-41.
106. Morein B. The iscom: an immunostimulating system. Immunol Lett. 1990;25(1):281-3.
107. Rimmelzwaan GF, Osterhaus AD. A novel generation of viral vaccines based on the ISCOM matrix. Pharm Biotechnol. 1995;6:543-58.
108. Mowat AM, Reid G. Preparation of immune stimulating complexes (ISCOMs) as adjuvants. Curr Protoc Immunol. 2001 May;Chapter 2:Unit 2 11.
109. Rimmelzwaan G, Baars M, Van Beek R, Van Amerongen G, Claas E, Osterhaus A. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol. 1997;78(4):757-65.
110. Sjolander S, Drane D, Davis R, Beezum L, Pearse M, Cox J. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine. 2001 Jul 16;19(28-29):4072-80.
111. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, Bates J, Osterhaus AD. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine. 2000 Dec 8;19(9-10):1180-7.
112. Felnerova D, Viret J-F, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15(6):518-29.
113. Clements M BR, Murphy B. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984;323(8379): 705-8.
114. Huckriede A, Bungener L, Daemen T, Wilschut J. Influenza virosomes in vaccine development. Methods Enzymol. 2003;373:74-91.
115. Glück R, Mischler R, Finkel B, Que J, Cryz Jr S, Scarpa B. Immunogenicity of new virosome influenza vaccine in elderly people. The Lancet. 1994;344(8916):160-3.
116. Mischler R, Metcalfe IC. Inflexal® V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20:B17-B23.
117. Zurbriggen R, Novak-Hofer I, Seelig A, Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog Lipid Res. 2000;39(1):3-18.
118. Bomsel M, Tudor D, Drillet A-S, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34(2):269-80.
119. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines. 2007;6(5):711-21.
120. Mason HS, Lam D, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A. 1992;89(24):11745-9.
121. Zhou B, Zhang Y, Wang X, Dong J, Wang B, Han C, Yu J, Li D. Oral administration of plant based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. Vaccine. 2010;28(37):6021-7.
122. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med. 1998;4(5):607-9.
123. Lycke N, Bemark M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 2010;3(6):556-66.
124. Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett. 2005;97(2):181-8.
125. Plant A, Williams NA. Modulation of the immune response by the cholera-like enterotoxins. Curr Top Med Chem. 2004;4(5):509-19.
126. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan Gl, Mills KH, Rappuoli R, Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 2001 Mar 21;19(17-19):2534-41.
127. Vajdy M, Lycke N. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology. 1992;75(3):488.
128. Hörnquist E, Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol. 1993;23(9):2136-43.
129. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986;59(2):301-8.
130. Neidleman J, Vajdy M, Ugozzoli M, Ott G, O'hagan D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology. 2000;101(1):154-60.
131. Gustafson G, Rhodes M. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992;143(5):483-8.
132. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigenspecific immunity via the TLR4 ligands MPL™ adjuvant and Ribi. 529. Expert Rev Vaccines. 2003;2(2):219-29.
133. Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol. 2001;126(2):135-9.
134. Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT, Michalek SM. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun. 2000;68(10):5509-16.
135. Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun. 2004;72(5):2507-12.
136. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546-9.
137. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 1987;3:342-7.
138. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-5.
139. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28(6):2045-54.
140. Jones TR, Obaldia III N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999;17(23):3065-71.
141. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp160 envelope proteins. Clin Chem Lab Med. 1999;37(3):199-204.
142. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun. 1999 Aug;67(8):3719-26.
143. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.
144. McCluskie MJ, Davis HL. Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998;161(9):4463-6.
145. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1995;13(1-2):1-55.
146. Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng CA Meyer in the mouse. Agents Actions. 1984;15(3-4):386-91.
147. Bangham A, Horne R. Action of saponin on biological cell membranes. 1962.
148. Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Cormet-Boyaka E, Kirk KL, Kensil CR, McGhee JR. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol. 2001;166(4):2283-90.
149. Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, Okuda K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol. 1998;72(6):4931-9.
150. Heath A, Playfair J. Cytokines as immunological adjuvants. Vaccine. 1992;10(7):427-34.
151. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol. 1998;68(2):122-38.
152. Childers NK, Tong G, Mitchell S, Kirk K, Russell MW, Michalek SM. A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect Immun. 1999;67(2):618-23.
153. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):81-96.
154. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine. 2003 Mar 28;21(13-14):1400-8.
155. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine. 1998 Dec;16(20):2039-46.
156. Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R. Effective nasal influenza vaccine delivery using chitosan. Vaccine. 2005 Aug 15;23(35):4367-74.
157. Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, Ward BJ. A novel intranasal Protollin™ based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine. 2005;23(11):1374-83.
158. Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Protollin™: a novel adjuvant for intranasal vaccines. Vaccine. 2004;22(27):3691-7.
159. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239(1):178-96.
160. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185(10):5677-82.
161. Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun. 2006;74(2):1113-20.